Excellent use of time guys. Though CYP making a 5-year low of $0.30, the CYP trolls fell they will have been rewarded. There is demand by the way. I will happily buy more under $0.30 if some of you trolls are game to short sell CYP?
The formal SCUlpTOR trial news is disappointing, but hardly surprising and out of the control of CYP, just as the NIH trial of C-19 ARDS was for MSB (and royally messed up to the detriment of wider society, not just MSB shareholders). You boys might as well be saying "your plight is as crap as ours was". The recent performance of CYP and MSB in trials has been hugely disappointing in both. Its just degrees of. It is no wonder both are pretty much on 5 year lows. One day you guys will wake up to shared synergies despite the different approaches.
Contrary to CYP's release, there HAVE been human clinical studies that suggest MSC's DO have "the ability to produce a tissue regenerative response, leading to a potential breakthrough in the US$11.6bn1 global osteoarthritis market". Which bodes well for CYP and the sector generally.
CYP Price at posting:
30.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)